Q-omics provides the consensus-scored HNRNPA1P30 profile across patient tissues and cancer cell-line models. HNRNPA1P30 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P30 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, HNRNPA1P30 RNA expression shows 8,171 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where HNRNPA1P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P30 survival associations across molecular data types. HNRNPA1P30 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P30 RNA expression–survival associations across cancer types. High HNRNPA1P30 expression shows unfavorable associations in CHOL and SARC, but favorable associations in BLCA, THCA, BRCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for HNRNPA1P30 RNA expression.
This table summarizes HNRNPA1P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P30 shows lower tumor expression in UCEC and higher tumor expression in HNSC, STAD, CHOL, KIRC and LUSC. The HNSC box plot shows higher HNRNPA1P30 RNA expression in tumor versus normal tissue (log2 FC = +0.084, t-test p = .016).
This table shows molecular features associated with HNRNPA1P30 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P30 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
